ESC 365 - Prevalence of transthyretin amyloid cardiomyopathy in patients hospitalised for heart failure with preserved ejection fraction in an LATAM center.

ESC Professional Premium Access

Prevalence of transthyretin amyloid cardiomyopathy in patients hospitalised for heart failure with preserved ejection fraction in an LATAM center.

Session: Cardiac amyloidosis, sarcoidosis, and inflammation

Topic: Heart Failure with Preserved Ejection Fraction (HFpEF)

Speaker: Mr S. Decotto (Buenos Aires, AR)

Event: ESC Congress 2024

Congress Presentation

Add to my library

About the speaker

Mr Santiago Decotto

Italian Hospital of Buenos Aires, Buenos Aires (Argentina)

0 follower

8 more presentations in this session

Delays in diagnosis and treatment initiation of ATTR cardiac amyloidosis: a real-world data analysis

Speaker: Doctor J. Vogel (Essen, DE)

Transthyretin stabiliser therapy in patients with transthyretin amyloid cardiomyopathy: a systematic review and meta-analysis

Speaker: Mr V. Ribeiro (Teresina, BR)

Biomarkers for monitoring patients with cardiac amyloidosis during transthyretin-stabilizer therapy

Speaker: Doctor J. Vogel (Essen, DE)

Relationship between changes in renal function after acute phase of tafamidis administration and left ventricular diastolic function at mid-term follow-up in transthyretin cardiac amyloidosis

Speaker: Ms A. Senda (Kobe, JP)

Prevalence of amyloidosis among patients with mild to severe aortic stenosis. Validation of screening parameters.

Speaker: Doctor F. Voss (Duesseldorf, DE)

Access the full session

Cardiac amyloidosis, sarcoidosis, and inflammation

Speakers: Mr S. Decotto, Doctor J. Vogel, Mr V. Ribeiro, Doctor J. Vogel, Ms A. Senda...

About the event

ESC Congress 2024

30 August - 2 September 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources